Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Clinical Studies

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

British Journal of Cancer volume 128, pages 30–41 (2023)Cite this article

Subjects

A Correction to this article was published on 25 January 2023

This article has been updated

Abstract

Background

This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours.

Methods

Patients with various malignancies were administered gedatolisib (90‒310 mg intravenously every week [QW]) plus docetaxel (arm A) or cisplatin (arm B) (each 75 mg/m2 intravenously Q3W) or dacomitinib (30 or 45 mg/day orally). The safety and tolerability of combination therapies were assessed during dose escalation; objective response (OR) and safety were assessed during dose expansion.

Results

Of 110 patients enrolled, 107 received gedatolisib combination treatment. Seven of 70 (10.0%) evaluable patients had dose-limiting toxicities; the most common was grade 3 oral mucositis (n = 3). Based upon reprioritisation of the sponsor’s portfolio, dose expansion focused on arm B, gedatolisib (180 mg QW) plus cisplatin in patients (N = 22) with triple-negative breast cancer (TNBC). OR (95% CI) was achieved in four of ten patients in first-line (overall response rate 40.0% [12.2–73.8%]) and four of 12 in second/third-line (33.3% [9.9–65.1%]) settings. One patient in each TNBC arm (10%, first-line; 8.3%, second/third-line) achieved a complete response.

Conclusions

Gedatolisib combination therapy showed an acceptable tolerability profile, with clinical activity at the recommended Phase 2 dose in patients with TNBC.

Clinical trial

ClinicalTrial.gov: NCT01920061.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Waterfall plots of best changes (%) in target lesions in patients with measurable disease in response-evaluable set during Part 1 of the study.
Fig. 2: Response to treatment in patients with triple-negative breast cancer participating in Part 2 of the study.

Similar content being viewed by others

Data availability

On request, and subject to certain criteria, conditions and exceptions, Celcuity, Inc. will provide access to individual de-identified participant data from Celcuity sponsored interventional clinical studies conducted for medicines (1) for indications that have been approved or (2) where development has been terminated. A brief research proposal will be assessed and form the basis of a data-sharing agreement. Data requests may be submitted by using the form provided at https://www.celcuity.com/contact/. https://www.nature.com/documents/aj-research-data-policy-type-3.pdf.

Change history

References

  1. Gohr K, Hamacher A, Engelke LH, Kassack MU. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer. 2017;17:711.

    Article  Google Scholar 

  2. Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 2013;32:253–65.

    Article  CAS  Google Scholar 

  3. Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5’-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010;53:2636–45.

    Article  CAS  Google Scholar 

  4. Langdon SP, Kay C, Um IH, Dodds M, Muir M, Sellar G, et al. Evaluation of the dual mTOR/PI3K inhibitors gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models. Sci Rep. 2019;9:18742.

    Article  CAS  Google Scholar 

  5. Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res. 2015;21:1888–95.

    Article  CAS  Google Scholar 

  6. Huang Y, Xue X, Li X, Jia B, Pan CX, Li Y, et al. Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer. Adv Ther. 2020;3:2000075.

  7. Yan C, Yang J, Saleh N, Chen S-C, Ayers GD, Abramson VG, et al. Inhibition of the PI3K/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors in breast cancer. Int J Mol Sci. 2021;22:5207.

    Article  CAS  Google Scholar 

  8. Wainberg Z, Shapiro G, Curigliano G, Kristeleit R, Leong S, Alsina M, et al. Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib. J Clin Oncol. 2016;34:2566.

    Article  Google Scholar 

  9. Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7:653–63.

    Article  Google Scholar 

  10. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007;63:429–36.

    Article  CAS  Google Scholar 

  11. Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, et al. A phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018;9:31709–18.

    Article  Google Scholar 

  12. Sharma P, Abramson VG, O’Dea AP, Nye L, Mayer IA, Pathak HB, et al. Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer. Clin Cancer Res. 2021;27:3896–904.

    Article  CAS  Google Scholar 

  13. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628–37.

    Article  CAS  Google Scholar 

  14. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33:1902–9.

    Article  CAS  Google Scholar 

  15. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051–60.

    Article  CAS  Google Scholar 

  16. Choy L, Hagenbeek TJ, Solon M, French D, Finkle D, Shelton A, et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res. 2017;77:1439–52.

    Article  CAS  Google Scholar 

  17. Hegde M, Joshi MB. Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors. J Cancer Res Clin. 2021;147:937–71.

    Article  CAS  Google Scholar 

  18. Li Y, Liu HT, Chen X, Wang YW, Tian YR, Ma RR, et al. Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer. Oncogene. 2022;41:361–71.

    Article  CAS  Google Scholar 

  19. Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017;1868:123–31.

    Article  CAS  Google Scholar 

  20. Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Tr. 2018;170:213–9.

    Article  CAS  Google Scholar 

  21. Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18:e841–e850.

    Article  CAS  Google Scholar 

  22. Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, et al. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer. 2019;19:96.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank the patients, their families, and/or caregivers, investigators, and site personnel who have supported and contributed to this study. Eva Ciruelos at the University Hospital, Madrid, Spain, is acknowledged for her early contributions to this study. Medical writing support was provided by Sue Reinwald, PhD, of Engage Scientific Solutions (funded by Pfizer) and Michael G Baker, PhD, of Haselwood Biosciences (funded by Celcuity).

Funding

This study was sponsored by Pfizer.

Author information

Author notes

  1. These authors contributed equally: Giuseppe Curigliano, Geoffrey I. Shapiro.

Authors and Affiliations

  1. Istituto Europeo di Oncologia, IRCCS, Milano, Italy

    Giuseppe Curigliano

  2. University of Milan, Milano, Italy

    Giuseppe Curigliano

  3. Dana-Farber Cancer Institute, Boston, MA, USA

    Geoffrey I. Shapiro

  4. University College London, Cancer Institute, London, UK

    Rebecca S. Kristeleit

  5. Phase 1 Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

    Albiruni R. Abdul Razak

  6. University of Colorado Cancer Center, Aurora, CO, USA

    Stephen Leong

  7. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

    Maria Alsina

  8. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

    Antonio Giordano

  9. BC Cancer, Vancouver, BC, Canada

    Karen A. Gelmon

  10. University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, AL, USA

    Erica Stringer-Reasor

  11. University of Michigan/Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

    Ulka N. Vaishampayan

  12. University of Oxford, Oxford, UK

    Mark Middleton

  13. Fox Chase Cancer Center, Philadelphia, PA, USA

    Anthony J. Olszanski

  14. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

    Hope S. Rugo

  15. Pfizer, San Diego, CA, USA

    Kenneth A. Kern, Nuzhat Pathan & Rachelle Perea

  16. Pfizer, Groton, CT, USA

    Kristen J. Pierce

  17. Celcuity, Minneapolis, MD, USA

    Sarah C. Mutka

  18. David Geffen School of Medicine at University of California, Los Angeles, CA, USA

    Zev A. Wainberg

Authors
  1. Giuseppe Curigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey I. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca S. Kristeleit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albiruni R. Abdul Razak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Alsina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karen A. Gelmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Erica Stringer-Reasor
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ulka N. Vaishampayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mark Middleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Anthony J. Olszanski
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hope S. Rugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kenneth A. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Nuzhat Pathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Rachelle Perea
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kristen J. Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Sarah C. Mutka
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Zev A. Wainberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GC, GIS, EC, KK, KJP and HSR contributed to the conception and design of the study. All authors contributed to the acquisition, analysis, or interpretation of data, and to drafting or revising the submitted manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. Dr. Curigliano (corresponding and co-first author) and Dr. Shapiro (co-first author) confirm they had full access to the data in the study and final responsibility for the decision to submit for publication.

Corresponding author

Correspondence to Giuseppe Curigliano.

Ethics declarations

Competing interests

GC: research funding: Merck; personal consultation fees: Pfizer, Roche, AstraZeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Eli Lilly; Ellipsis, and Merck. GIS: research funding: Eli Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology; Advisory boards: Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis, CytomX Therapeutics and Blueprint Medicines; holds a patent titled “Dosage regimen for sapacitabine and seliciclib” also issued to Cyclacel Pharmaceuticals, and a pending patent titled “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition” together with Liam Cornell. RSK has received grants from MSD and Clovis; Consultancy: Basilea, Pharmamar; Advisor: AstraZeneca, GSK, iTEOS, Eisai, and InCyte. ARAR: research funding: Pfizer. SL: research funding: institution funding as principal investigator on trials for Pfizer, BMS, Deciphera, and Karyopharma; employment: on faculty at University of Colorado at the time of this research, since June 2020 an employee of Merck. MA: consultancy: BMS, MSD, Lilly, and Servier. AG: author declared no conflict of interest. KAG: research funding: Pfizer, AstraZeneca, and BMS; advisory board member: Pfizer, Novartis, Eli Lilly, Roche, Merck, Mylan, AstraZeneca, Gilead, and Ayala. ES-R: research funding: Susan G. Komen, V Foundation and NIH; employment: principal or sub-investigator of Pfizer sponsor clinical trials, fees paid to the institution; consultancy fees: Eli Lilly, Merck, Macrogenics, and AstraZeneca. UNV: research support: Merck, BMS and Astellas Inc. Consulting and Honoraria: Merck, Exelixis, BMS, Pfizer, AAA, Alkermes, Bayer, and EMD-Serono. MM: Grants: Roche, AstraZeneca, GRAIL; grants and personal fees: GSK; personal fees and other: BiolineRx, BMS, Novartis; grants, personal fees and other: Immunocore; other: Pfizer, Regeneron; personal fees, non-financial support and other: Merck/MSD; personal fees and non-financial support: Replimune, personal fees: Kineta and Silicon Therapeutics. AJO: research funding: Pfizer, Merck, and BMS – compensation for ad board. HSR: research support: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala and Gilead; honoraria: Puma, Samsung and NAPO. KAK: an employee of and holds stock options in Pfizer. NP: research funding: Pfizer; an employee of and holds stock options in Pfizer. RP: Was an employee and held stock options in Pfizer at the time the work was done. KJP: an employee of and holds stock options in Pfizer. SCM: an employee of and holds stock options in Celcuity; holds stock in Alpine Immune Sciences. ZAW: research funding: Plexxikon, Novartis and BMS; advisory boards: AstraZeneca, Eli Lilly, Genentech, Merck KGaA/EMD-Serono, Ipsen, Bayer, Daiichi Sankyo, Seagen, Merck, BMS, Amgen, Five Prime and Macrogenics Molecular Templates.

Ethics approval and consent to participate

The protocol, its amendments, and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each site. Study procedures followed the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines and all local regulatory requirements. All patients provided informed consent before participating in any study-related procedure.

Consent to publish

Not applicable.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: As per Italian regulation, the two affiliations for Dr. Curigliano (Instituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Curigliano, G., Shapiro, G.I., Kristeleit, R.S. et al. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer 128, 30–41 (2023). https://doi.org/10.1038/s41416-022-02025-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-02025-9

This article is cited by

Search

Advanced search

Quick links